While The Street is leaning toward a favorable vote for MedImmune Inc.'s FluMist as an intranasal influenza vaccine, it's not so clear whether Seattle-based Corixa Inc. will get the nod for its cancer drug, Bexxar. (BioWord Today)

While politicians in Washington haven't decided whether they should ban therapeutic cloning, scientists in California have forged ahead with a plan to establish a research institute that will use stem cell biology to study cancer and other diseases.

While politicians in Washington haven't decided whether they should ban therapeutic cloning, scientists in California have forged ahead with a plan to establish a research institute that will use stem cell biology to study cancer and other diseases.